The announcement was made after market hours yesterday, 21 June 2018.

Meanwhile, the S&P BSE Sensex was down 79.64 points, or 0.22% to 35,352.75.

On the BSE, 25,000 shares were traded in the counter so far compared with average daily volumes of 30,000 shares in the past two weeks. The stock had hit a high of Rs 1,420 and a low of Rs 1,381 so far during the day. The stock hit a 52-week high of Rs 1,515.40 on 19 June 2018. The stock hit a 52-week low of Rs 882.55 on 22 August 2017.

AstraZeneca Pharma India announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of Durvalumab (ImfinziTM) in India.

Durvalumab provides a treatment option for patient with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma. Durvalumab is a patented product of AstraZeneca global.

AstraZeneca Pharma India reported net profit of Rs 3.22 crore in Q4 March 2018 as against net loss of Rs 9.56 crore in Q4 March 2017. Net sales rose 30.27% to Rs 150.73 crore in Q4 March 2018 over Q4 March 2017.

AstraZeneca Pharma India is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma & COPD.

Powered by Capital Market - Live News

AstraZeneca Pharma India announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses.

Durvalumab provides a treatment option for patient with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.

Durvalumab is a patented product of AstraZeneca global.

Powered by Capital Market - Live News

Net profit of Astrazeneca Pharma India reported to Rs 3.22 crore in the quarter ended March 2018 as against net loss of Rs 9.56 crore during the previous quarter ended March 2017. Sales rose 30.27% to Rs 150.73 crore in the quarter ended March 2018 as against Rs 115.71 crore during the previous quarter ended March 2017.

For the full year,net profit rose 29.23% to Rs 25.91 crore in the year ended March 2018 as against Rs 20.05 crore during the previous year ended March 2017. Sales rose 5.02% to Rs 571.00 crore in the year ended March 2018 as against Rs 543.70 crore during the previous year ended March 2017.

Powered by Capital Market - Live News

The result was announced after market hours yesterday, 21 May 2018.

Meanwhile, the S&P BSE Sensex was up 87.07 points, or 0.25% to 34,703.20.

On the BSE, 2,418 shares were traded in the counter so far compared with average daily volumes of 6,049 shares in the past two weeks. The stock had hit a high of Rs 1,203.65 and a low of Rs 1,150 so far during the day. The stock hit a 52-week high of Rs 1,278 on 7 November 2017. The stock hit a 52-week low of Rs 882.55 on 22 August 2017.

Net sales rose 30.27% to Rs 150.73 crore in Q4 March 2018 over Q4 March 2017.

AstraZeneca Pharma India is the operating company covering manufacturing, sales and marketing activities. It has an innovative portfolio to address the unmet needs in non-communicable diseases such as diabetes, heart disease, cancer, asthma & COPD.

Powered by Capital Market - Live News